IRIDEX (IRIX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $12.6 million, up 7% sequentially but flat to down 1.7% year-over-year, with net loss of $2.7 million ($0.16 per share), slightly improved from Q2 2023.

• Six-month revenue declined 8.2% to $24.4 million, with a net loss of $6.1 million and EPS of $(0.38).

• Glaucoma segment stabilized after Medicare reimbursement uncertainty, but system sales remain below prior year; Retina segment showed strong growth.

• Strategic review process ongoing, aiming for a value-enhancing transaction within the fiscal year.

• Recent $3.4 million convertible note financing, with an option for an additional $1.5 million, strengthens liquidity.

Financial highlights

• Gross profit for Q2 2024 was $5.1 million, with a gross margin of 40.7%, down from 41.7% in Q2 2023.

• Operating expenses for Q2 were $7.8 million, down from $8.3 million year-over-year due to cost reductions.

• Cash and cash equivalents were $4.1 million at quarter-end, with an additional $3.4 million raised post-quarter via convertible notes.

• Working capital was $8.9 million at quarter-end, compared to $14.5 million at December 30, 2023.

• Deferred revenue at quarter-end was $11.6 million, with $9.0 million related to exclusivity distribution rights.

Outlook and guidance

• Management expects cost savings and recent financing to support liquidity for the next 12 months.

• Strategic review process targeted to conclude with a transaction by fiscal year-end.

• Macroeconomic uncertainty, inflation, and capital spending delays may continue to impact demand.